Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 97Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 81Lymphoma 62Lymphoma, Mantle-Cell 59Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Recurrence 35Lymphoma, B-Cell 24Leukemia 20Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Multiple Myeloma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 8Lymphoma, Large-Cell, Immunoblastic 7Intraocular Lymphoma 7Neoplasms 6Lymphoma, Extranodal NK-T-Cell 6Leukemia, B-Cell 6Leukemia, Hairy Cell 5Leukemia-Lymphoma, Adult T-Cell 4

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Lenalidomide × Lymphoid × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡